Vincenzo Mazzaferro, Carlo Battiston, Carlo Sposito – 27 October 2017 – The success of liver transplantation (LT) in curing cancer (particularly hepatocellular carcinoma and hepatic metastases from neuroendocrine tumors) is based on the augmented oncologic potentials of the total hepatectomy and on restrictive criteria applied to patient selection. Consensus on the grade of expansion of conventional limits and implementation of alternative indications to LT (cholangiocarcinoma and metastases from colorectal cancer) has not been reached.

Shuichi Aoki, Mark Cobbold, Andrew X. Zhu, Dan G. Duda – 27 October 2017

Atoosa Rabiee, James P.A. Hamilton – 27 October 2017

Vera C. Mazurak, Puneeta Tandon, Aldo J. Montano‐Loza – 26 October 2017 – Cirrhosis is the most common indication for liver transplantation (LT) worldwide. Malnutrition is present in at least two‐thirds of patients with cirrhosis awaiting LT. It negatively impacts survival, quality of life, and the ability to respond to stressors, such as infection and surgery. Muscle wasting or sarcopenia is the most objective feature of chronic protein malnutrition in cirrhosis, and this condition is associated with increased morbidity and mortality before and after LT.

26 October 2017

26 October 2017

Federico Piñero, Marcelo Silva – 25 October 2017

Masaaki Mino, Keishi Kanno, Kousuke Okimoto, Akiko Sugiyama, Nobusuke Kishikawa, Tomoki Kobayashi, Junya Ono, Kenji Izuhara, Tsuyoshi Kobayashi, Toshikazu Ohigashi, Hideki Ohdan, Susumu Tazuma – 25 October 2017 – Periostin, a secreted matricellular protein, has been reported to induce epithelial‐mesenchymal transition (EMT), which increases motility and invasiveness in various epithelial cancer cells.

This session provides a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting®.Michael W. Fried Insook Kim Insook Kim, PhD is a clinical pharmacology team leader for gastroenterology and hepatology products in the Office of Clinical Pharmacology at FDA. Since she joined FDA as a clinical pharmacology reviewer in 2007, she has been involved in numerous IND and NDA review and has provided regulatory and scientific guidance for product development in the areas of gastroenterology, hepatology, and inborn errors of metabolism.

As HCV therapies now achieve high rates of SVR across a broad spectrum of individuals in patient care, there is a need to consider those HCV-infected persons who are not or may have difficulty accessing care or engaging in HCV therapy. Additionally, aspects related to prevention of reinfection are relevant in these difficult to reach populations.